Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.56 |
| ▸ | CHKA | P35790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775404 | 1.00 | SORD (0.56) | SORDCHKAMAPTGPR119DRD4 | |
| SCHEMBL209844 | 0.98 | SORD (0.54) | SORDCHKAMAPTGPR119DRD4 | |
| SCHEMBL209842 | 0.98 | SORD (0.54) | SORDCHKAMAPTGPR119DRD4 | |
| SCHEMBL29611181 | 0.98 | SORD (0.54) | SORDCHKAMAPTGPR119DRD4 | |
| SCHEMBL9767811 | 0.91 | — | — | |
| Imidazole SCHEMBL19693057 | 0.85 | SORD (0.48) | SORDCHKAMAPTGPR119DRD4 | |
| SCHEMBL24742884 | 0.84 | SORD (0.50) | SORDALDH1A1TSHRGSK3BROCK1 | |
| SCHEMBL2224541 | 0.83 | SORD (0.53) | SORDGPR119DRD4AKT1ROCK1 | |
| SCHEMBL2103794 | 0.83 | SORD (0.53) | SORDGPR119DRD4AKT1ROCK1 | |
| SCHEMBL194151 | 0.82 | PLD1 (0.59) | SORDDRD4ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| EP-4061813-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021256569-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | 佐藤製薬株式会社 | 2021-12-23 | — | — | WO | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20200377481-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200377481-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals ,Inc. | 2011-01-20 | — | — | US | disclosed |
| CN-101472584-A | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-01 | — | — | CN | disclosed |
| US-7544698-B2 | Indoles and benzoimidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-09 | — | — | US | disclosed |
| EP-2010172-A2 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007117401-A2 | INDOLES AND BENZOIMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238771-A1 | Indoles and benzoimidazoles as histamine H4 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-11 | — | — | US | disclosed |
| EP-0335348-B2 | Mesomorphic compound, ferroelectric liquid crystal composition containing same and ferroelectric liquid crystal device | CANON KK (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-0335348-B1 | Mesomorphic compound, ferroelectric liquid crystal composition containing same and ferroelectric liquid crystal device | CANON KK (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5034151-A | Laminate with 1,3,4-oxadiazole compoumd as liquid crystal | CANON KABUSHIKI KAISHA (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0335348-A2 | Mesomorphic compound, ferroelectric liquid crystal composition containing same and ferroelectric liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238771-A1 | Indoles and benzoimidazoles as histamine H4 receptor modulators | HRH4, HRH3, HRH1 | SORD 4580/4885CHKA 814/4885MAPT 1381/4885 |
| US-20200377481-A1 | SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NOS1, NOS3, NOS2 | SORD 364/4885CHKA 1709/4885MAPT 656/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | SORD 3130/4885CHKA 3963/4885MAPT 2789/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | SORD 2461/4885CHKA 872/4885MAPT 4405/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | SORD 4280/4885CHKA 555/4885MAPT 673/4885 |
| US-20110015157-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | SORD 364/4885CHKA 1896/4885MAPT 3693/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SORD 3130/4885CHKA 3963/4885MAPT 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.